Omada Health, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan MacDonald from Needham reiterated a Buy rating on the stock and has a $24.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan MacDonald has given his Buy rating due to a combination of factors that highlight Omada Health, Inc.’s strong market position and growth potential. The company demonstrated impressive performance in its first quarter as a public entity, achieving a remarkable 51.6% increase in membership. This growth is attributed not only to the interest from employers seeking alternatives or complementary solutions to GLP-1 medications but also to a broad-based increase in average revenue per member.
MacDonald believes that Omada Health is strategically positioned to capitalize on the ongoing demand driven by rising healthcare costs associated with GLP-1s. The company’s current valuation, coupled with what is perceived as conservative guidance, further supports the Buy rating. Omada Health is identified as a promising digital health opportunity for the latter half of 2025, making it one of MacDonald’s preferred investment ideas in the sector.
In another report released today, Barclays also maintained a Buy rating on the stock with a $24.00 price target.